https://www.lamassubiotech.com/

Lamassu BioTech, Cleveland, OH (2026)

03/12/2026

🧬 𝐖𝐡𝐲 𝐢𝐬 𝐩𝟓𝟑 𝐜𝐚𝐥𝐥𝐞𝐝 𝐭𝐡𝐞 “𝐠𝐮𝐚𝐫𝐝𝐢𝐚𝐧 𝐨𝐟 𝐭𝐡𝐞 𝐠𝐞𝐧𝐨𝐦𝐞”?

Because it sits at the heart of the cell’s defense — protecting against DNA errors, uncontrolled growth, and malignant transformation. When functioning properly, p53:
- Arrests the 𝐜𝐞𝐥𝐥 𝐜𝐲𝐜𝐥𝐞 upon detecting DNA damage, granting time for repair.
- 𝐈𝐧𝐢𝐭𝐢𝐚𝐭𝐞𝐬 𝐚𝐩𝐨𝐩𝐭𝐨𝐬𝐢𝐬 when damage is irreparable.
- Regulates 𝐃𝐍𝐀 𝐫𝐞𝐩𝐚𝐢𝐫 𝐩𝐚𝐭𝐡𝐰𝐚𝐲𝐬, 𝐬𝐞𝐧𝐞𝐬𝐜𝐞𝐧𝐜𝐞, 𝐦𝐞𝐭𝐚𝐛𝐨𝐥𝐢𝐬𝐦, 𝐢𝐦𝐦𝐮𝐧𝐞 𝐬𝐮𝐫𝐯𝐞𝐢𝐥𝐥𝐚𝐧𝐜𝐞, 𝐚𝐧𝐝 𝐞𝐯𝐞𝐧 𝐚𝐧𝐠𝐢𝐨𝐠𝐞𝐧𝐞𝐬𝐢𝐬.

But the reality is sobering: 𝐓𝐏𝟓𝟑 𝐢𝐬 𝐭𝐡𝐞 𝐦𝐨𝐬𝐭 𝐟𝐫𝐞𝐪𝐮𝐞𝐧𝐭𝐥𝐲 𝐦𝐮𝐭𝐚𝐭𝐞𝐝 𝐠𝐞𝐧𝐞 𝐢𝐧 𝐜𝐚𝐧𝐜𝐞𝐫 — 𝐟𝐨𝐮𝐧𝐝 𝐢𝐧 𝐨𝐯𝐞𝐫 𝟓𝟎% 𝐨𝐟 𝐡𝐮𝐦𝐚𝐧 𝐭𝐮𝐦𝐨𝐫𝐬.

Despite decades of research, restoring p53 function remains a formidable challenge. However, recent breakthroughs provide renewed optimism:
- A comprehensive mutational scan using CRISPR covering over 9,000 TP53 variants has pinpointed specific mutations that may be 𝐩𝐡𝐚𝐫𝐦𝐚𝐜𝐨𝐥𝐨𝐠𝐢𝐜𝐚𝐥𝐥𝐲 𝐫𝐞𝐚𝐜𝐭𝐢𝐯𝐚𝐭𝐚𝐛𝐥𝐞, opening new avenues for precision therapy.
- Insights into p53’s structural fragility — especially its evolutionarily optimized but unstable DNA-binding domain — reveal 𝐰𝐡𝐲 𝐢𝐭'𝐬 𝐛𝐨𝐭𝐡 𝐡𝐢𝐠𝐡𝐥𝐲 𝐚𝐝𝐚𝐩𝐭𝐢𝐯𝐞 𝐚𝐧𝐝 𝐩𝐚𝐫𝐭𝐢𝐜𝐮𝐥𝐚𝐫𝐥𝐲 𝐯𝐮𝐥𝐧𝐞𝐫𝐚𝐛𝐥𝐞 𝐭𝐨 𝐦𝐮𝐭𝐚𝐭𝐢𝐨𝐧 — knowledge that’s valuable for drug design.

At Lamassu BioTech, our novel genetically-targeted therapy SA53 is built to respect this complexity. By 𝐭𝐚𝐫𝐠𝐞𝐭𝐢𝐧𝐠 𝐭𝐡𝐞 𝐌𝐃𝐌𝟐–𝐩𝟓𝟑 𝐚𝐱𝐢𝐬, 𝐰𝐞 𝐚𝐢𝐦 𝐭𝐨 𝐫𝐞𝐚𝐰𝐚𝐤𝐞𝐧 𝐩𝟓𝟑’𝐬 𝐠𝐮𝐚𝐫𝐝𝐢𝐚𝐧 𝐫𝐨𝐥𝐞 and unlock its power to suppress tumors.

𝐒𝐜𝐢𝐞𝐧𝐜𝐞 𝐞𝐯𝐨𝐥𝐯𝐞𝐬. 𝐒𝐨 𝐝𝐨𝐞𝐬 𝐨𝐮𝐫 𝐰𝐨𝐫𝐤.

⚠️ Disclaimer: SA53 is investigational. Visit LamassuBiotech.com for updates on SA53 and other novel therapies under development..
📚 Sources: Levine AJ et al., Nat Rev Cancer 2020

03/10/2026

⏳ 𝐈𝐧 𝐚𝐜𝐮𝐭𝐞 𝐩𝐚𝐧𝐜𝐫𝐞𝐚𝐭𝐢𝐭𝐢𝐬, 𝐭𝐢𝐦𝐞 𝐦𝐚𝐭𝐭𝐞𝐫𝐬.

For many patients, an episode of AP begins suddenly — severe abdominal pain brings them to the 𝐞𝐦𝐞𝐫𝐠𝐞𝐧𝐜𝐲 𝐫𝐨𝐨𝐦 (𝐄𝐑). While some cases remain mild, the disease can escalate quickly:
➡️ 𝐃𝐚𝐲 𝟎 → 𝐄𝐑
➡️ 𝐇𝐨𝐬𝐩𝐢𝐭𝐚𝐥𝐢𝐳𝐚𝐭𝐢𝐨𝐧 for monitoring and supportive care
➡️ 𝐈𝐂𝐔 𝐚𝐝𝐦𝐢𝐬𝐬𝐢𝐨𝐧 for patients who progress to severe disease

📊 Roughly 𝟏 𝐢𝐧 𝟓 𝐩𝐚𝐭𝐢𝐞𝐧𝐭𝐬 (≈𝟐𝟎%) 𝐰𝐢𝐭𝐡 𝐚𝐜𝐮𝐭𝐞 𝐩𝐚𝐧𝐜𝐫𝐞𝐚𝐭𝐢𝐭𝐢𝐬 𝐝𝐞𝐯𝐞𝐥𝐨𝐩 𝐚 𝐬𝐞𝐯𝐞𝐫𝐞 𝐟𝐨𝐫𝐦 𝐫𝐞𝐪𝐮𝐢𝐫𝐢𝐧𝐠 𝐢𝐧𝐭𝐞𝐧𝐬𝐢𝐯𝐞 𝐜𝐚𝐫𝐞, often with life-threatening organ failure.

Despite decades of research, 𝐭𝐫𝐞𝐚𝐭𝐦𝐞𝐧𝐭 𝐫𝐞𝐦𝐚𝐢𝐧𝐬 𝐬𝐮𝐩𝐩𝐨𝐫𝐭𝐢𝐯𝐞 𝐨𝐧𝐥𝐲 — fluids, pain management, and vigilant observation. 𝐍𝐨 𝐝𝐫𝐮𝐠 𝐡𝐚𝐬 𝐞𝐯𝐞𝐫 𝐛𝐞𝐞𝐧 𝐚𝐩𝐩𝐫𝐨𝐯𝐞𝐝 to address the underlying biology of this condition.

At Lamassu BioTech, we are advancing 𝐑𝐀𝐁𝐈-𝟕𝟔𝟕, 𝐚𝐧 𝐢𝐧𝐯𝐞𝐬𝐭𝐢𝐠𝐚𝐭𝐢𝐨𝐧𝐚𝐥 𝐭𝐡𝐞𝐫𝐚𝐩𝐲 designed to target the root processes that drive severe acute pancreatitis. Our goal is to change the trajectory — so that fewer patients move from the ER to the ICU.

⚠️ Disclaimer: RABI-767 is investigational. Visit LamassuBiotech.com for updates on RABI-767 and other novel therapies under development.
📚 Source: Tenner S et al., Am J Gastroenterol. 2013.

03/05/2026

🧬 𝐩𝟓𝟑 𝐢𝐬 𝐨𝐧𝐞 𝐨𝐟 𝐭𝐡𝐞 𝐦𝐨𝐬𝐭 𝐬𝐭𝐮𝐝𝐢𝐞𝐝 𝐠𝐞𝐧𝐞𝐬 𝐢𝐧 𝐜𝐚𝐧𝐜𝐞𝐫 𝐛𝐢𝐨𝐥𝐨𝐠𝐲 — 𝐛𝐮𝐭 𝐚𝐥𝐬𝐨 𝐨𝐧𝐞 𝐨𝐟 𝐭𝐡𝐞 𝐦𝐨𝐬𝐭 𝐦𝐢𝐬𝐮𝐧𝐝𝐞𝐫𝐬𝐭𝐨𝐨𝐝.

Let’s bust a few myths:
𝐌𝐲𝐭𝐡 𝟏: “𝐩𝟓𝟑 𝐢𝐬 𝐣𝐮𝐬𝐭 𝐨𝐧𝐞 𝐠𝐞𝐧𝐞.”
👉 Reality: It regulates a network of pathways controlling cell cycle, DNA repair, apoptosis, and more.
𝐌𝐲𝐭𝐡 𝟐: “𝐀𝐥𝐥 𝐜𝐚𝐧𝐜𝐞𝐫𝐬 𝐥𝐨𝐬𝐞 𝐩𝟓𝟑.”
👉 Reality: Some retain wild-type p53, but it’s silenced by regulators like MDM2.

𝐒𝐜𝐢𝐞𝐧𝐜𝐞 𝐞𝐯𝐨𝐥𝐯𝐞𝐬. 𝐒𝐨 𝐝𝐨𝐞𝐬 𝐨𝐮𝐫 𝐰𝐨𝐫𝐤. That’s why at Lamassu BioTech, we are advancing 𝐒𝐀𝟓𝟑, 𝐨𝐮𝐫 𝐧𝐨𝐯𝐞𝐥 𝐠𝐞𝐧𝐞𝐭𝐢𝐜𝐚𝐥𝐥𝐲-𝐭𝐚𝐫𝐠𝐞𝐭𝐞𝐝 𝐭𝐡𝐞𝐫𝐚𝐩𝐲 𝐭𝐚𝐫𝐠𝐞𝐭𝐢𝐧𝐠 𝐭𝐡𝐞 𝐌𝐃𝐌𝟐–𝐩𝟓𝟑 𝐚𝐱𝐢𝐬.

⚠️ Disclaimer: SA53 is investigational. Visit LamassuBiotech.com for updates on SA53 and other novel therapies under development.
📚 Source: Levine AJ. Nat Rev Cancer. 2020.

03/03/2026

🚀 𝐍𝐨𝐯𝐞𝐥𝐭𝐲 𝐢𝐧 𝐝𝐫𝐮𝐠 𝐝𝐞𝐯𝐞𝐥𝐨𝐩𝐦𝐞𝐧𝐭 𝐢𝐬𝐧’𝐭 𝐣𝐮𝐬𝐭 𝐚𝐛𝐨𝐮𝐭 𝐬𝐩𝐞𝐞𝐝 — 𝐢𝐭’𝐬 𝐚𝐛𝐨𝐮𝐭 𝐝𝐢𝐫𝐞𝐜𝐭𝐢𝐨𝐧.

For decades, acute pancreatitis (AP) has remained a 𝐭𝐡𝐞𝐫𝐚𝐩𝐞𝐮𝐭𝐢𝐜 𝐝𝐞𝐬𝐞𝐫𝐭:
- Hundreds of thousands of hospitalizations each year.
- Severe AP mortality up to 20–40%.

𝟎 𝐚𝐩𝐩𝐫𝐨𝐯𝐞𝐝 𝐝𝐫𝐮𝐠𝐬 𝐰𝐨𝐫𝐥𝐝𝐰𝐢𝐝𝐞.

That is why 𝐑𝐀𝐁𝐈-𝟕𝟔𝟕 is different:
🧬 𝐌𝐞𝐜𝐡𝐚𝐧𝐢𝐬𝐦: RABI-767 is a novel small-molecule 𝐥𝐢𝐩𝐚𝐬𝐞 𝐢𝐧𝐡𝐢𝐛𝐢𝐭𝐨𝐫. By blocking the breakdown of triglycerides into toxic free fatty acids, it aims to address the 𝐫𝐨𝐨𝐭 𝐦𝐞𝐜𝐡𝐚𝐧𝐢𝐬𝐦 𝐨𝐟 𝐨𝐫𝐠𝐚𝐧 𝐟𝐚𝐢𝐥𝐮𝐫𝐞 in severe AP.
📈 𝐂𝐥𝐢𝐧𝐢𝐜𝐚𝐥 𝐦𝐨𝐦𝐞𝐧𝐭𝐮𝐦:
- Licensed from Mayo Clinic, advancing with translational science at its core.
- 𝐅𝐚𝐬𝐭 𝐓𝐫𝐚𝐜𝐤 𝐝𝐞𝐬𝐢𝐠𝐧𝐚𝐭𝐢𝐨𝐧 𝐛𝐲 𝐭𝐡𝐞 𝐅𝐃𝐀 (𝟐𝟎𝟐𝟒).
- 𝐂𝐮𝐫𝐫𝐞𝐧𝐭𝐥𝐲 𝐢𝐧 𝐏𝐡𝐚𝐬𝐞 𝟐𝐚 𝐜𝐥𝐢𝐧𝐢𝐜𝐚𝐥 𝐞𝐯𝐚𝐥𝐮𝐚𝐭𝐢𝐨𝐧.

This is not about treating symptoms — it’s about rethinking pancreatitis at its origin. At Lamassu BioTech, our mission is to turn decades of unmet need into a future with real therapeutic options.

⚠️ Disclaimer: RABI-767 is investigational. Visit LamassuBiotech.com for updates on RABI-767 and other novel therapies under development.
📚 Sources: Arrivo BioVentures, FDA Fast Track announcement 2024; Forsmark CE, N Engl J Med. 2016.

02/27/2026

Success comes from having a sound understanding of the industry's landscape and what differentiates your company from your competitors. That was the message from biotech leaders during this week's "Catalyzing Cancer Innovation" panel discussion, hosted by I am Biotech's BIOPartnering™. Lamassu BioTech CEO Gabi Hanna MD shared his insights on the challenges and opportunities for companies looking for success in 2026 alongside Rodman & Renshaw Senior Biotechnology Analyst Michael G King Jr, Bantam Pharmaceutical CEO Michael Stocum, Creatv MicroTech, Inc. CBO Ron Baker, and Oncode Accelerator Business Development Manager Federica Frati.

02/04/2026

On , Lamassu Biotech stands united with the global cancer community as we all work to bring hope and healing to those suffering. Nearly 2 million new cases of cancer are diagnosed annually in the United States, with half of all forms of human cancer involving the mutation of the P53 gene. That's why our team works tirelessly each and every day to advance our investigational SA553-therapy, a first-in-class, small-molecule MDM2 inhibitor. This is a significant unmet need globally. We believe that this genetically targeted therapy can bring new hope for patients, especially those dealing with rare cancers who currently have no good treatment options.

01/16/2026

It was a great week for our CEO Gabi Hanna MD. and CSO Greg Palmer at J.P. Morgan's 44th Annual Healthcare Conference. This will be a pivotal year as our team advances our SA53 MDM2 inhibitor program, a next-generation approach for patients with p53 wild-type solid tumors. This treatment offers hope for those with rare forms of cancer and a targeted alternative where traditional therapies have failed.

01/12/2026

Our CEO, Gabi Hanna, MD, recently sat down with RBV Quarterly to discuss what makes a successful leader. As Dr. Hanna shared, “In biotech, you are always racing against the clock. Patent life starts on day one, and every delay reduces your chances of success. Market windows open and close quickly, and when you miss them, the opportunity disappears, regardless of the quality of your science. Time isn’t a preference to optimize — it is a decisive constraint that shapes
everything we do.”

🔗 in the comments.

01/06/2026

🎗️ Sarcomas: rare, but deeply impactful.

📊 In 2025, the U.S. will see an estimated ~13,520 new cases of soft-tissue sarcoma.

⏳ Outcomes remain strongly stage-dependent:
•83% 5-year survival when localized.
• Only 17% 5-year survival once metastatic.

🔎 Although sarcomas represent just ~1% of adult cancers, they account for ~15% of pediatric cancers — underscoring the urgent unmet need.

At Lamassu Biotech, our novel therapy SA53 targets the MDM2–p53 axis, with the goal of advancing precision oncology in sarcoma and beyond.

⚠️ Disclaimer: SA53 is investigational. Visit LamassuBiotech.com for updates on SA53 and other novel therapies under development.
📚 Source: American Cancer Society, 2025.

12/30/2025

🐈 𝐂𝐚𝐭𝐬 𝐡𝐢𝐝𝐞 𝐢𝐥𝐥𝐧𝐞𝐬𝐬 𝐰𝐞𝐥𝐥 — 𝐚𝐧𝐝 𝐩𝐚𝐧𝐜𝐫𝐞𝐚𝐭𝐢𝐭𝐢𝐬 𝐢𝐬 𝐧𝐨 𝐞𝐱𝐜𝐞𝐩𝐭𝐢𝐨𝐧.

Subtle symptoms like loss of appetite, lethargy, and dehydration often go unnoticed, delaying diagnosis. The vagueness of these signs, paired with limited treatment options in veterinary medicine, highlights a significant unmet need.

At Lamassu Pets, our work on 𝐑𝐀𝐁𝐈 𝟕𝟔𝟕 𝐮𝐧𝐝𝐞𝐫𝐬𝐜𝐨𝐫𝐞𝐬 𝐭𝐡𝐢𝐬 𝐩𝐚𝐫𝐚𝐥𝐥𝐞𝐥 𝐜𝐡𝐚𝐥𝐥𝐞𝐧𝐠𝐞 𝐚𝐜𝐫𝐨𝐬𝐬 𝐛𝐨𝐭𝐡 𝐡𝐮𝐦𝐚𝐧 𝐚𝐧𝐝 𝐯𝐞𝐭𝐞𝐫𝐢𝐧𝐚𝐫𝐲 𝐡𝐞𝐚𝐥𝐭𝐡.

⚠️ Disclaimer: RABI 767 is investigational. Visit LamassuBiotech.com for updates on RABI-767 and other novel therapies under development.
📚 Source: Animal Biome blog by Dr. Tonya Cooksey, DVM (Aug 15, 2025)

12/23/2025

Lamassu BioTech's leadership team, CEO Gabi Hanna MD. and CSO Greg Palmer, PhD, will be on the ground for the J.P. Morgan Healthcare Conference this January to share a year of breakthrough progress and clinical momentum. Following highly encouraging data, we are ready to discuss the future of our two lead programs:

🔬 SA53 | Precision Oncology
We are advancing our MDM2 inhibitor program for p53-wildtype tumors. Ongoing Phase 1/2 clinical data continues to show a favorable safety profile across multiple targeted cancer types, reinforcing our confidence in this genetically targeted approach.

🐾 RABI-767 | Acute Pancreatitis
We are scaling our "One Health" approach to address this significant unmet need. We are particularly excited to advance our LamassuPet animal health program—bringing RABI-767 to canines while simultaneously progressing the human clinical pathway alongside our partners.

We look forward to connecting with industry leaders and investors to discuss how we can accelerate these life-saving therapies for both human and animal patients.

12/23/2025

🎯 A target doesn’t equal a therapy.

In oncology, identifying a molecular target is only the first step. Turning that insight into a safe and effective treatment requires more than just “hitting the target.” It requires a framework of hypotheses that guide every stage of drug design.

At Lamassu Biotech, our work with SA53 — an investigational therapy targeting the MDM2–p53 axis — is built on three pillars:
✔ Biomarkers → defining which patients are most likely to benefit, and how to measure that benefit in trials.
✔ Resistance pathways → anticipating how tumors may adapt, so strategies can evolve before resistance takes hold.
✔ Safety from day 0 → ensuring that every step of development considers tolerability and risk management alongside efficacy.

This disciplined approach is how we move from basic science toward precision oncology.

The p53 pathway is one of the most studied in cancer biology — yet translating that knowledge into therapies has proven challenging. We believe that carefully integrating biomarker science, resistance biology, and safety data can shift that equation.

At Lamassu, our mission is to rethink the MDM2–p53 axis and build therapies designed with patients in mind, from day one.

Lamassu BioTech

03/12/2026

03/10/2026

03/05/2026

03/03/2026

02/27/2026

02/04/2026

01/16/2026

01/12/2026

01/06/2026

12/30/2025

12/23/2025

12/23/2025

Address

Website

Alerts

Contact The Practice

Shortcuts

Share

Category